SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* | 2. Date of Event | | 3. Issuer Name and Ticker or Trading Symbol | | | | | |
|---|--|--------------------|--|--|------------------------------------|---|--|--|
| EXCEL MEDICAL FUND LP (Month/Day/Year) 06/28/2017 | | | AILERON THERAPEUTICS INC [ALRN] | | | | | |
| (Last) (First) (Middle) 800 BOYLSTON STREET, SUITE 2825 | . 00/20/2017 | | 4. Relationship of Reporting Perso (Check all applicable) Director X | ., | er (N | 5. If Amendment, Date of Original Filed (Month/Day/Year) | | |
| (Street) BOSTON MA 02199 | | | Officer (give title below) | Other (spe below) | | pplicable Line) Form filed b | t/Group Filing (Check by One Reporting Person by More than One | |
| (City) (State) (Zip) | | | | | | Reporting P | 615011 | |
| | Table I - No | n-Derivat | ive Securities Beneficiall | y Owned | | | | |
| 1. Title of Security (Instr. 4) | | | 2. Amount of Securities Beneficially Owned (Instr. 4) | | | 4. Nature of Indirect Beneficial Ownership (Instr. 5) | | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | |
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 1 | ies | 4. Conversio | | 6. Nature of Indirect p Beneficial Ownership (Instr. 5) | |
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Price of Derivative Security | Direct (D) or Indirect (I) (Instr. 5) | | |
| Series D Preferred Stock | (1) | (1) | Common Stock | 597,167 | (1) | D ⁽⁵⁾ | | |
| Series E-2 Preferred Stock | (2) | (2) | Common Stock | 133,842 | (2) | D ⁽⁵⁾ | | |
| Series E-3 Preferred Stock | (3) | (3) | Common Stock | 116,091 | (3) | D ⁽⁵⁾ | | |
| Series F Preferred Stock | (4) | (4) | Common Stock | 108,998 | (4) | D ⁽⁵⁾ | | |
| | e) | - | | | | | | |
| (Street) BOSTON MA 0219 |) | - | | | | | | |
| (City) (State) (Zip) | | - | | | | | | |
| 1. Name and Address of Reporting Person* <u>Gullans Steven R. Ph.D.</u> | | | | | | | | |
| (Last) (First) (Middl 800 BOYLSTON STREET, SUITE 2825 | e) | | | | | | | |
| (Street) BOSTON MA 0219 |) | _ | | | | | | |
| (City) (State) (Zip) | | | | | | | | |
| 1. Name and Address of Reporting Person [*] Blume Frederick R. | | - | | | | | | |
| (Last) (First) (Middl 800 BOYLSTON STREET, SUITE 2825 | e) | | | | | | | |
| (Street) | | - | | | | | | |

| BOSTON | МА | 02199 | | | | | |
|---|---------------|----------|--|--|--|--|--|
| (City) | (State) | (Zip) | | | | | |
| 1. Name and Address of Reporting Person* | | | | | | | |
| <u>Enriquez Juan</u> | | | | | | | |
| (Last) | (First) | (Middle) | | | | | |
| 800 BOYLSTON STREET, SUITE 2825 | | | | | | | |
| (Street) | | | | | | | |
| BOSTON | MA | 02199 | | | | | |
| (City) | (State) | (Zip) | | | | | |
| 1. Name and Address of Reporting Person* Excel Medical Ventures, LLC | | | | | | | |
| Excel Medical | ventures, LLC | | | | | | |
| (Last) | (First) | (Middle) | | | | | |
| 800 BOYLSTON STREET, SUITE 2825 | | | | | | | |
| (Street) | | | | | | | |
| BOSTON | MA | 02199 | | | | | |
| (City) | (State) | (Zip) | | | | | |

Explanation of Responses:

1. The Series D Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

2. The Series E-2 Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

3. The Series E-3 Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

4. The Series F Preferred Stock is convertible into Common Stock on a 9.937-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

5. Excel Medical Ventures, LLC is the general partner of Excel Medical Fund, L.P. Steven R. Gullans, Frederick R. Blume and Juan Enriquez are the Managing Directors of Excel Medical Ventures, LLC. Excel Medical Ventures, LLC and each of these individuals may be deemed to share voting and dispositive power with respect to all shares held by Excel Medical Fund, L.P. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Remarks:

| <u>/s/ Fredrick R. Blume, Excel</u> <u>Medical Fund, L.P.</u> | <u>06/28/2017</u> |
|--|-------------------|
| /s/ Steven R. Gullans | 06/28/2017 |
| /s/ Fredrick R. Blume | 06/28/2017 |
| <u>/s/ Juan Enriquez</u> | 06/28/2017 |
| <u>/s/ Fredrick R. Blume, Excel</u> <u>Medical Ventures, LLC.</u> | <u>06/28/2017</u> |
| ** Signature of Reporting Person | Date |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.